TY - JOUR
T1 - Rare thyroid malignancies in Europe
T2 - Data from the information network on rare cancers in Europe (RARECAREnet)
AU - Locati, Laura
AU - Cavalieri, Stefano
AU - Dal Maso, Luigino
AU - Busco, Susanna
AU - Anderson, Lesley Ann
AU - Botta, Laura
AU - Bento, Maria José
AU - Carulla, Marià
AU - Chirlaque López, Maria Dolores
AU - Fusco, Mario
AU - Guevara, Marcela
AU - Innos, Kaire
AU - Børge Johannesen, Tom
AU - Micallef, Rita
AU - Minicozzi, Pamela
AU - Panato, Chiara
AU - Petrova, Dafina
AU - Rubio-Casadevall, Jordi
AU - Smailyte, Giedre
AU - Francesca Vitale, Maria
AU - Trama, Annalisa
N1 - Funding Information:
This work was supported by.
Funding Information:
the Italian Association for Cancer Research (AIRC 2015) (grant IG 16921) and by the Ministry of Health (5X1000, year 2013 to Centro di Riferimento Oncologico di Aviano [CRO] IRCCS, Aviano).
Publisher Copyright:
© 2020 Elsevier Ltd
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/9
Y1 - 2020/9
N2 - Objective: Limited information is available on the incidence of rare thyroid cancer (TC) subtypes: anaplastic (ATC) and medullary (MTC). The aim of this study was to describe incidence variations and trends across European countries of all TC subtypes. Materials and methods: We used the RARECAREnet database including 80721 TC incident cases in the period 2000–2007 from 77 population-based cancer registries (CRs) in Europe. In the trend analyses, we included 68890 TC cases from 53 CRs with at least 6 years of incidence data in the years 2000–2007. Results: In Europe age-standardised incidence rates (ASR) in women were <0.3/100,000 for MTC and ATC whereas ASR were 5.3/100,000 for papillary thyroid cancer (PTC) and 1.1/100,000 for follicular TC (FTC). Corresponding ASRs in men were <0.2/100,000 for MTC and ATC, 1.5 for PTC and 0.4 for FTC. Across countries and in both sexes the incidence of FTC and MTC was moderately correlated (r ~ 0.5) with that of PTC, while a less marked correlation (r < 0.4) emerged for ATC ASRs. The changes of the PTC ASRs across countries and time were weakly (r < 0.3) or moderately (r ~ 0.5) correlated to the changes of the other subtypes for both sexes. Conclusion: The huge increase and heterogeneity between countries of PTC incidence has a small influence on the trends and variations of MTC and ATC in Europe. Large-scale epidemiological and clinical registry-based studies are warranted to increase knowledge about the rarest TC subtypes. This information would be fundamental for the design of new clinical trials and for inference.
AB - Objective: Limited information is available on the incidence of rare thyroid cancer (TC) subtypes: anaplastic (ATC) and medullary (MTC). The aim of this study was to describe incidence variations and trends across European countries of all TC subtypes. Materials and methods: We used the RARECAREnet database including 80721 TC incident cases in the period 2000–2007 from 77 population-based cancer registries (CRs) in Europe. In the trend analyses, we included 68890 TC cases from 53 CRs with at least 6 years of incidence data in the years 2000–2007. Results: In Europe age-standardised incidence rates (ASR) in women were <0.3/100,000 for MTC and ATC whereas ASR were 5.3/100,000 for papillary thyroid cancer (PTC) and 1.1/100,000 for follicular TC (FTC). Corresponding ASRs in men were <0.2/100,000 for MTC and ATC, 1.5 for PTC and 0.4 for FTC. Across countries and in both sexes the incidence of FTC and MTC was moderately correlated (r ~ 0.5) with that of PTC, while a less marked correlation (r < 0.4) emerged for ATC ASRs. The changes of the PTC ASRs across countries and time were weakly (r < 0.3) or moderately (r ~ 0.5) correlated to the changes of the other subtypes for both sexes. Conclusion: The huge increase and heterogeneity between countries of PTC incidence has a small influence on the trends and variations of MTC and ATC in Europe. Large-scale epidemiological and clinical registry-based studies are warranted to increase knowledge about the rarest TC subtypes. This information would be fundamental for the design of new clinical trials and for inference.
KW - Anaplastic thyroid cancer
KW - Cancer registries
KW - Epidemiology
KW - Incidence
KW - Medullary thyroid cancer
KW - Thyroid cancer
UR - http://www.scopus.com/inward/record.url?scp=85085178294&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85085178294&partnerID=8YFLogxK
U2 - 10.1016/j.oraloncology.2020.104766
DO - 10.1016/j.oraloncology.2020.104766
M3 - Article
C2 - 32454415
AN - SCOPUS:85085178294
VL - 108
JO - Oral Oncology
JF - Oral Oncology
SN - 1368-8375
M1 - 104766
ER -